Comparison of 68Ga-Pentixafor and 18F-FDG PET Results in the Patients Who Underwent Both
| 68Ga-pentixafor | 18F-FDG | ||||||
| Type of malignancy | Mets (n) | SUVmax | T/B | VD | SUVmax | T/B | VD |
| NSCLC | 3 | 5.2 | 2.6 | 1/4 | 29.3 | 11.6 | 4/4 |
| Melanoma | 3 | 4.5 | 2.2 | 3/3 | 17.7 | 10.2 | 3/3 |
| Melanoma | 1 | 3.9 | 1.8 | 1/1 | 11.1 | 5.5 | 1/1 |
| Breast cancer | 1 | 5.5 | 3.2 | 1/1 | 7.8 | 4.3 | 1/1 |
| Breast cancer* | 5 | 3.5 | 1.5 | 3/6 | 9.2 | 4.6 | 6/6 |
| Sarcoma | 1 | 2.1 | 2.6 | 1/1 | 2.4 | 3.0 | 1/1 |
| Sarcoma | >5 | 5.3 | 5.0 | 5/5 | 6.7 | 4.0 | 5/5 |
| Sarcoma | 1 | 5.0 | 3.2 | 1/1 | 6.3 | 3.3 | 1/1 |
| Sarcoma | 3 | 3.2 | 1.5 | 1/3 | 11.1 | 5.3 | 3/3 |
| CUP | 2 | 13.8 | 8.1 | 2/2 | 26.9 | 14.2 | 2/2 |
↵* Lesions for which primary tumor was present.
Mets = metastases; VD = visual detectability; CUP = cancer of unknown primary.
SUVmax and T/B data are mean. Maximum of 5 metastases was recorded if patient presented with more than 5 metastases. Overall, 27 lesions were evaluated (2 primary tumors and 25 metastases).